Bain Capital Life Sciences Fund II, L.P. - 17 Oct 2025 SCHEDULE 13G Report for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC)

Filing Manager
Bain Capital Life Sciences Fund II, L.P.
Reporting Manager
BCLS II Equity Opportunities, LP
Security
C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol
CCCC
Shares outstanding
96,960,000 shares
Disclosed Ownership
6,060,000 shares
Ownership
6.2%
Form type
SCHEDULE 13G
Filing time
24 Oct 2025, 16:30:06 UTC
Date of event
17 Oct 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Bain Capital Life Sciences Fund II, L.P. disclosed 6.2% ownership in C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC) on 17 Oct 2025."

Quick Takeaways

  • Bain Capital Life Sciences Fund II, L.P. filed SCHEDULE 13G for C4 Therapeutics, Inc. Common Stock, par value $0.0001 per share (CCCC).
  • Disclosed ownership: 6.2%.
  • Date of event: 17 Oct 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 24 Oct 2025, 16:30.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Bain Capital Life Sciences Fund II, L.P. 1.1% 991,188 0 991,188 /s/ Andrew Hack Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
BCIP Life Sciences Associates, LP 0.13% 120,722 0 120,722 /s/ Andrew Hack Andrew Hack, Authorized Signatory of Boylston Coinvestors, LLC
BCLS II Equity Opportunities, LP 6.2% 6,060,000 0 6,060,000 /s/ Andrew Hack Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC

Sponsored